AMMS-CanSino to Start Clinical Trial of China Ebola Vaccine

A China-discovered Ebola vaccine, developed jointly by the Bioengineering Institute of China's Academy of Military Medical Sciences (AMMS) and Tianjin CanSino Biotechnology, has been approved to begin clinical trials. The Bioengineering Institute has been at work on an Ebola vaccine since 2006. After the 2014 outbreak, the research team updated the virus strain to the Zaire-Guinea type currently prevalent in West Africa. To accelerate development of the vaccine, the Institute collaborated with CanSino and the National Institutes for Food and Drug Control. More details.... Share this with colleagues: // //